Autonomix Medical, Inc. (NASDAQ:AMIX) has experienced a substantial decline in short interest, with figures showing a decrease of 62.1% from November 30, 2023, to December 15, 2023. The short interest fell from 353,480 shares to 133,864 shares during this period, indicating a shift in investor sentiment regarding the company’s stock.
Currently, short sales represent approximately 2.1% of Autonomix Medical’s total shares, reflecting a decrease in bearish bets on the stock. The average daily trading volume stands at 221,552 shares, resulting in a days-to-cover ratio of 0.6 days. This metric suggests that the existing short positions could be covered quickly, contributing to a potentially positive outlook for the stock.
Stock Performance Overview
On Friday, shares of Autonomix Medical opened at $0.58, with a one-year low of $0.56 and a one-year high of $4.58. The stock’s performance has been under scrutiny, with its 50-day simple moving average at $0.88 and the 200-day simple moving average at $1.12. The company possesses a market capitalization of approximately $3.98 million, a price-to-earnings ratio of -0.12, and a beta of -2.87, indicating higher volatility compared to the overall market.
The firm last disclosed its quarterly earnings on November 12, 2023, reporting an earnings per share (EPS) of ($1.38), which met analysts’ expectations. Analysts forecast that Autonomix Medical will post an annual EPS of -10 for the current year, highlighting ongoing financial challenges as it continues to develop its technology.
About Autonomix Medical
Founded in 2014 and headquartered in The Woodlands, Texas, Autonomix Medical, Inc. is a development-stage medical device company focused on advancing technologies for diagnosing and treating disorders of the peripheral nervous system. The company’s innovative platform includes a catheter-based microchip-enabled sensing array designed to detect and differentiate peripheral neural signals, positioning it at the forefront of medical technology advancements.
As the company continues to navigate the complexities of the medical device industry, these recent changes in short interest may reflect a broader confidence among investors. Autonomix Medical’s ongoing developments and market strategies will be critical to its future performance.
